Loading stock…

Sichuan Biokin Pharmaceutical Co.,Ltd. (688506) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Sichuan Biokin Pharmaceutical Co.,Ltd.

688506Market cap $15BPrice $36.1

Country🇨🇳China

SectorHealthcare

IndustryPharmaceuticals

Develops and sells innovative small-molecule and biologic drugs targeting cancer and metabolic diseases in China. Its ADC therapy sisunatovir became one of the first homegrown Chinese oncology drugs licensed globally, earning a landmark deal with a major Western pharma giant.

In Bastion Portfolios?

52W Return-25%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+52%10

Revenue Forecast

Rev CAGR (1y)+4%4

Rev CAGR (3y)+8%6

Rev CAGR (5y)+34%10

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+3Loss1

Quality

Margins

EBIT Margin-49%1

Net Income Margin-62%1

Free Cash Flow Margin-63%1

Debt

Net Debt/EBITDAna–

Efficiency

ROE-42%1

ROA-17%1

Earnings Stability22

GEAR+VERY WEAK9

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)na–

P/BV21.71

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-1.6%2

Dividend Yieldna–

Momentum

Short term

1 month return-1%7

3 month return-20%2

YTD return-25%2

Mid term

Price vs 52wHigh60%2

1 year return-36%1

Long term

3 year return+152%9

5 year return+655%10

Risk Shield

Price Risk

Beta-0.210

Volatility55%3

Free Cash Flow

Free Cash Flow Margin-63%1

Free Cash Flow Yield-1.6%2

Quality

ROCE-17%1

Earnings Stability22

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

688506Sichuan Biokin Pharmaceutical Co.,Ltd.

Revenue FY25$360M

GROWTH RATING↗

AVERAGE61 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+52%10

Revenue, next 1Y+4%4

Revenue, next 3Y, CAGR+8%6

Revenue, next 5Y, CAGR+34%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 52%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 8%/yr over the next 3 years, ahead of most of the market.7/10

The runway holds up: revenue is set to grow 34%/yr over five years.10/10

WATCH

A mid-pack grower, ahead of 61% of companies worldwide.

Revenue grew 52%/yr over the last 3 years; forecasts see it cooling to 8%/yr.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A middle-of-the-pack grower that is slowing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

688506Sichuan Biokin Pharmaceutical Co.,Ltd.

Total return Current83.2%

Price return Current83.2%

MOMENTUM RATING↗

AVERAGE37 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-1%7

3-month return-20%2

YTD return-25%2

MID & LONG-TERM▾SCORE

% of 52-week high60%2

1-year return-36%1

3-year return+152%9

5-year return+655%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +152% over three years and +655% over five, ahead of 90% of the market.

Strong recent results. The stock is outperforming over the past month (-1%).

WATCH

None flagged.

WEAKNESSES

It's down 36% over the past year, now 40% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-20%) and so far this year (-25%).

BOTTOM LINE

Outperformer in a Drawdown

A proven multi-year compounder now in a meaningful pullback well below its 52-week high. This is the classic fork: either a buy-the-dip in an intact uptrend, or the early stage of a trend change. Wait for the short-term slide to stabilise before adding. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Biokin Pharma. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

688506Sichuan Biokin Pharmaceutical Co.,Ltd.

Revenue FY25$360M

GROWTH RATING↗

AVERAGE61 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+52%10

Revenue, next 1Y+4%4

Revenue, next 3Y, CAGR+8%6

Revenue, next 5Y, CAGR+34%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 52%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 8%/yr over the next 3 years, ahead of most of the market.7/10

The runway holds up: revenue is set to grow 34%/yr over five years.10/10

WATCH

A mid-pack grower, ahead of 61% of companies worldwide.

Revenue grew 52%/yr over the last 3 years; forecasts see it cooling to 8%/yr.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A middle-of-the-pack grower that is slowing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

688506Sichuan Biokin Pharmaceutical Co.,Ltd.

Total return Current83.2%

Price return Current83.2%

MOMENTUM RATING↗

AVERAGE37 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-1%7

3-month return-20%2

YTD return-25%2

MID & LONG-TERM▾SCORE

% of 52-week high60%2

1-year return-36%1

3-year return+152%9

5-year return+655%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +152% over three years and +655% over five, ahead of 90% of the market.

Strong recent results. The stock is outperforming over the past month (-1%).

WATCH

None flagged.

WEAKNESSES

It's down 36% over the past year, now 40% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-20%) and so far this year (-25%).

BOTTOM LINE

Outperformer in a Drawdown

04Value

Are you paying a fair price for it?

Stop guessing on Biokin Pharma. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community